静脉利多卡因用于结肠手术肠道功能恢复:一项随机临床试验
ALLEGRO试验在27家英国医院将590例择期微创结肠切除患者随机分配至2%静脉利多卡因组或生理盐水安慰剂组,比较术后72小时肠道功能恢复情况。结果显示,利多卡因组达到GI-3复合终点的患者比例为57.3%,安慰剂组为59.0%,校正绝对差异为-1.9%(95%CI -8.0%至4.2%),相对危险度为0.97(95%CI 0.88至1.07),11项次要终点均无显著差异。
要点
- 择期微创结肠切除患者围术期使用2%静脉利多卡因未改善术后72小时肠道功能恢复。
- 利多卡因组与安慰剂组GI-3复合终点恢复比例分别为57.3%和59.0%,差异无统计学意义。
- 两组的11项次要终点均无显著差异。
核心结论
- 在接受择期微创结肠切除的患者中,围术期给予2%静脉利多卡因未改善术后72小时的肠道功能恢复。
研究设计与样本
- ALLEGRO试验是一项在27家英国医院开展的随机、安慰剂对照、双盲试验。
- 共590例计划接受择期微创结肠切除(良性或恶性疾病)的成人按1:1随机分配至2%静脉利多卡因组或生理盐水安慰剂组。
- 招募时间为2018年8月13日至2023年4月11日,其中2020年3月20日至2020年7月6日暂停招募;最终随访日期为2023年8月10日。
- 随机后排除33例后,共有557例纳入分析(利多卡因组279例,安慰剂组278例;女性249例[44.7%];平均[标准差]年龄66[10.9]岁);532例(96%)接受了随机分配的治疗。
主要发现
- 术后72小时达到GI-3复合终点(耐受饮食且排气或排便)的患者比例:静脉利多卡因组160例(57.3%)vs 安慰剂组164例(59.0%),校正绝对差异为-1.9%(95%CI -8.0%至4.2%),相对危险度为0.97(95%CI 0.88至1.07)。
- 干预组与对照组在全部11项次要终点上均无显著差异。
关键数值与推荐
- 主要终点为术后72小时肠道功能恢复比例,采用GI-3复合终点定义:耐受饮食(连续3餐进食和饮水无明显恶心或呕吐)且排气或排便。
- 次要终点共11项,包括GI-3恢复时间、GI-2恢复时间(耐受经口饮食且排便)、延长性术后肠梗阻、术后恶心呕吐评分、镇痛总体获益评分、术后阿片类药物消耗量、恢复质量-15评分、生活质量(EuroQol五维度五水平量表)、加速康复方案依从性、达到医学定义出院标准的时间以及患者自评出院准备时间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite the recovery advantages of minimally invasive surgical techniques, delayed return of gut function after colectomy is a common barrier to timely discharge from hospital. OBJECTIVE: To evaluate the effect of 2% perioperative intravenous lidocaine infusion on return of gut function after elective minimally invasive colon resection. DESIGN, SETTING, AND PARTICIPANTS: The ALLEGRO trial was a randomized, placebo-controlled, double-blind trial conducted in 27 UK hospitals. A total of 590 adults scheduled for elective minimally invasive colon resection for benign or malignant disease were randomized 1:1 to 2% intravenous lidocaine or saline placebo. Enrollment occurred from August 13, 2018, to April 11, 2023, with a pause in recruitment from March 20, 2020, through July 6, 2020; final follow-up was on August 10, 2023. INTERVENTIONS: The intervention patients received 2% intravenous lidocaine administered as 1.5-mg/kg bolus at induction of anesthesia followed by 1.5 mg/kg/h for 6 or 12 hours. Control patients received 0.9% saline placebo for 6 or 12 hours. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with return of gut function at 72 hours after surgery, defined by the GI-3 composite end point of tolerating diet (ingestion of food and drink without significant nausea or vomiting for 3 consecutive meals) and passage of flatus or stool. There were 11 secondary outcomes, including time to GI-3 recovery, time to GI-2 recovery (tolerance of oral diet and passage of stool), prolonged postoperative ileus, postoperative nausea and vomiting score, Overall Benefit of Analgesia Score, postoperative opioid consumption, Quality of Recovery-15, quality of life (EuroQol 5-Dimension 5-Level), enhanced recovery protocol adherence, time to meeting medically defined criteria for discharge, and time to patient self-assessed readiness for discharge. RESULTS: The trial enrolled 590 patients (295 intervention, 295 control); after 33 postrandomization exclusions, 557 patients were included (279 intervention, 278 control; 249 female patients [44.7%]; mean [SD] age, 66 [10.9] years); 532 (96%) received the randomized treatment. Return of gut function as defined by the GI-3 composite outcome was achieved at 72 hours by 160 patients (57.3%) in the intravenous lidocaine group vs 164 patients (59.0%) in the placebo group (adjusted absolute difference, -1.9% [95% CI, -8.0% to 4.2%]; relative risk, 0.97 [95% CI, 0.88 to 1.07]). There was no significant difference between the intervention and control groups in any of the 11 secondary end points. CONCLUSIONS AND RELEVANCE: Among patients undergoing elective minimally invasive colon resection, perioperative administration of 2% intravenous lidocaine did not improve return of gut function at 72 hours. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN52352431.
引用
- Paterson H, Vadiveloo T, Innes K, et al. Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. JAMA. 2025. PMID: 39602290. doi:10.1001/jama.2024.23898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。